Display options
Cite
Moges B, Bitew A, Shewaamare A. Spectrum and the In Vitro Antifungal Susceptibility Pattern of Yeast Isolates in Ethiopian HIV Patients with Oropharyngeal Candidiasis. Int J Microbiol. 2016;2016:3037817doi: 10.1155/2016/3037817.
Moges, B., Bitew, A., & Shewaamare, A. (2016). Spectrum and the In Vitro Antifungal Susceptibility Pattern of Yeast Isolates in Ethiopian HIV Patients with Oropharyngeal Candidiasis. International journal of microbiology, 20163037817. https://doi.org/10.1155/2016/3037817
Moges, Birhan, et al. "Spectrum and the In Vitro Antifungal Susceptibility Pattern of Yeast Isolates in Ethiopian HIV Patients with Oropharyngeal Candidiasis." International journal of microbiology vol. 2016 (2016): 3037817. doi: https://doi.org/10.1155/2016/3037817
Moges B, Bitew A, Shewaamare A. Spectrum and the In Vitro Antifungal Susceptibility Pattern of Yeast Isolates in Ethiopian HIV Patients with Oropharyngeal Candidiasis. Int J Microbiol. 2016;2016:3037817. doi: 10.1155/2016/3037817. Epub 2016 Jan 05. PMID: 26880925; PMCID: PMC4736391.
Copy Download .nbib Format: NLM
Share it on

Int J Microbiol. 2016;2016:3037817. doi: 10.1155/2016/3037817. Epub 2016 Jan 05.

Spectrum and the In Vitro Antifungal Susceptibility Pattern of Yeast Isolates in Ethiopian HIV Patients with Oropharyngeal Candidiasis.

International journal of microbiology

Birhan Moges, Adane Bitew, Aster Shewaamare

Affiliations

  1. Department of Microbiology Quality Control, Ethiopian Food, Medicine and Healthcare Administration and Control Authority, Addis Ababa, Ethiopia.
  2. Department of Medical Laboratory Sciences, College of Health Sciences Addis Ababa University, Addis Ababa, Ethiopia.
  3. Department of Disease Prevention and Control, Zewditu Memorial Hospital, Addis Ababa, Ethiopia.

PMID: 26880925 PMCID: PMC4736391 DOI: 10.1155/2016/3037817

Abstract

Background. In Ethiopia, little is known regarding the distribution and the in vitro antifungal susceptibility profile of yeasts. Objective. This study was undertaken to determine the spectrum and the in vitro antifungal susceptibility pattern of yeasts isolated from HIV infected patients with OPC. Method. Oral pharyngeal swabs taken from oral lesions of study subjects were inoculated onto Sabouraud Dextrose Agar. Yeasts were identified by employing conventional test procedures and the susceptibility of yeasts to antifungal agents was evaluated by disk diffusion assay method. Result. One hundred and fifty-five yeast isolates were recovered of which 91 isolates were from patients that were not under HAART and 64 were from patients that were under HAART. C. albicans was the most frequently isolated species followed by C. glabrata, C. tropicalis, C. krusei, C. kefyr, Cryptococcus laurentii, and Rhodotorula species. Irrespective of yeasts isolated and identified, 5.8%, 5.8%, 12.3%, 8.4%, 0.6%, and 1.3% of the isolates were resistant to amphotericin B, clotrimazole, fluconazole, ketoconazole, miconazole, and nystatin, respectively. Conclusion. Yeast colonization rate of 69.2% and 31% resistance to six antifungal agents was documented. These highlight the need for nationwide study on the epidemiology of OPC and resistance to antifungal drugs.

References

  1. J Clin Microbiol. 2000 Apr;38(4):1563-8 - PubMed
  2. Oral Dis. 2002;8 Suppl 2:151-60 - PubMed
  3. Braz J Infect Dis. 2002 Jun;6(3):118-23 - PubMed
  4. J Med Microbiol. 2007 Feb;56(Pt 2):255-9 - PubMed
  5. J Clin Microbiol. 2003 Oct;41(10):4718-25 - PubMed
  6. Mycopathologia. 2009 Feb;167(2):81-7 - PubMed
  7. J Clin Microbiol. 1999 Dec;37(12):3896-900 - PubMed
  8. Oral Dis. 2004 May;10(3):145-50 - PubMed
  9. SADJ. 1999 Dec;54(12):605-8 - PubMed
  10. Spec Care Dentist. 2000 Sep-Oct;20(5):178-81 - PubMed
  11. Mycopathologia. 2007 Feb;163(2):67-73 - PubMed
  12. Clin Infect Dis. 1995 Oct;21(4):897-904 - PubMed
  13. BMC Oral Health. 2006 Aug 18;6:12 - PubMed
  14. Antimicrob Agents Chemother. 2000 Jun;44(6):1585-7 - PubMed
  15. J Antimicrob Chemother. 2007 Apr;59(4):767-71 - PubMed
  16. Mycopathologia. 2006 Jul;162(1):45-50 - PubMed
  17. BMC Infect Dis. 2013 Feb 12;13:82 - PubMed
  18. Clin Infect Dis. 2000 May;30(5):749-56 - PubMed
  19. Medicine (Baltimore). 2003 Jan;82(1):39-50 - PubMed
  20. J Antimicrob Chemother. 1999 Mar;43(3):419-22 - PubMed
  21. J Oral Pathol Med. 2000 Aug;29(7):336-41 - PubMed
  22. Oral Dis. 2000 Mar;6(2):106-11 - PubMed
  23. J Clin Microbiol. 2005 Nov;43(11):5721-32 - PubMed
  24. Clin Infect Dis. 1998 Feb;26(2):259-72; quiz 273-4 - PubMed
  25. Rev Iberoam Micol. 2005 Jun;22(2):83-92 - PubMed
  26. J Oral Pathol Med. 2002 Jan;31(1):5-10 - PubMed
  27. Mem Inst Oswaldo Cruz. 2004 Jun;99(4):425-31 - PubMed
  28. J Antimicrob Chemother. 2000 Aug;46(2):338-40 - PubMed
  29. Clin Microbiol Rev. 2007 Jan;20(1):133-63 - PubMed
  30. J Clin Microbiol. 1996 Feb;34(2):454-6 - PubMed
  31. Mycopathologia. 2001;149(2):63-8 - PubMed
  32. SADJ. 2002 Dec;57(11):479-82 - PubMed
  33. Braz Oral Res. 2011 Jan-Feb;25(1):28-33 - PubMed
  34. J Microbiol Immunol Infect. 2011 Jun;44(3):172-7 - PubMed
  35. Diagn Microbiol Infect Dis. 2002 Oct;44(2):169-74 - PubMed
  36. AIDS Patient Care STDS. 2000 Dec;14(12):627-35 - PubMed
  37. Mycoses. 1998 May-Jun;41(5-6):203-11 - PubMed
  38. J Med Microbiol. 2011 Sep;60(Pt 9):1312-6 - PubMed

Publication Types